Gainers
Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.
Gainers
Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.
Flywire (NASDAQ:FLYW) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.14) by 150 percent. This is a 59.77 percent increase over losses of $(0.87) per share from the same